Non-Small Cell
Lung Cancer

DKN-01 in Lung cancer

DKK1 is highly expressed in NSCLC and associated with shorter overall survival. DKN-01 has demonstrated activity as a monotherapy and in combination with chemotherapies and PD-1 antibody immune checkpoint inhibitors in preclinical models of NSCLC. In a clinical trial, DKN-01 demonstrated single agent activity in heavily-pretreated patients with NSCLC, including a patient with a partial response and nearly 50% of patients experiencing a best response of stable disease.

Posters for the lung cancer indication

• Phase 1 study evaluating the safety and efficacy of DKN-01, an investigational monoclonal antibody (Mab) in patients (pts) with advanced non-small cell lung cancer (ASCO 2014)